European Journal of Cancer
Volume 42, Issue 1 , Pages 31-41 , January 2006

Prevention and treatment of cancer cachexia: New insights into an old problem

  • Maurizio Muscaritoli

      Affiliations

    • Department of Clinical Medicine, University ‘La Sapienza’, Viale dell’Universita 37, 00185 Rome, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 06 4997 2016; fax: +39 06 446 1341.
    • Maurizio Muscaritoli and Maurizio Bossola contributed equally to this work.
    • ,
  • Maurizio Bossola

      Affiliations

    • Istituto di Clinica Chirurgica, Catholic University, Rome, Italy
    • Maurizio Muscaritoli and Maurizio Bossola contributed equally to this work.
    • ,
  • Zaira Aversa

      Affiliations

    • Department of Clinical Medicine, University ‘La Sapienza’, Viale dell’Universita 37, 00185 Rome, Italy
    • ,
  • Rocco Bellantone

      Affiliations

    • Istituto di Clinica Chirurgica, Catholic University, Rome, Italy
    • ,
  • Filippo Rossi Fanelli

      Affiliations

    • Department of Clinical Medicine, University ‘La Sapienza’, Viale dell’Universita 37, 00185 Rome, Italy

Received 10 June 2005 ,Revised 22 July 2005 ,Accepted 28 July 2005.

References 

  1. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52:72–91
  2. MacDonald N, Easson AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197:143–161
  3. Rossi Fanelli F, Cangiano C, Muscaritoli M, et al. Tumour-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition. 1995;11(S5):595–600
  4. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003;237:384–389
  5. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol. 2003;1(3):159–168
  6. Stepp L, Pakiz TS. Anorexia and cachexia in advanced cancer. Nurs Clin North Am. 2001;36(4):735–744
  7. Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol. 1999;8:133–141
  8. Laviano A, Meguid MM, Rossi Fanelli F. Improving food intake in anorectic cancer patients. Curr Opin Clin Nutr Metab Care. 2003;6(4):421–426
  9. Laviano A, Meguid MM, Rossi Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 2003;4:686–694
  10. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care. 1998;1:245–251
  11. Dempsey DT, Knox LS, Mullen JL, et al. Energy expenditure in malnourished patients with colorectal cancer. Arch Surg. 1996;121:789–795
  12. Gibney E, Elia M, Jebb SA, et al. Total energy expenditure in patients with non small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism. 1997;46:1412–1417
  13. Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994;219:325–331
  14. Jeevanandam M, Horowitz GD, Lowry SF, et al. Cancer cachexia and protein metabolism. Lancet. 1984;1:1423–1426
  15. Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1992;51:251–265
  16. Beck SA, Tisdale MJ. Production of a lipolytic and proteolytic factors by a murine tumour-producing cachexia in the host. Cancer Res. 1987;47:5919–5923
  17. Russel ST, Zimmerman TP, Domin BA, et al. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-α2-glycoprotei. Biochim Biophys Acta. 2004;1636:59–68
  18. Todorov PT, McDevitt TM, Meyer DJ, et al. Purification and characterisation of a tumour lipid-mobilising factor. Cancer Res. 1998;58:2353–2358
  19. Islam-Ali B, Khan S, Price SA, et al. Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer. 2001;85:758–763
  20. Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998;58:2359–2365
  21. Bing C, Russel ST, Beckett EE, et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br J Cancer. 2002;86(4):612–618
  22. Tisdale MJ. Cachexia in cancer patients. Nature. 2002;2:862–871
  23. Bing C, Brown M, King P, et al. Increased gene expression of brown fat uncoupling protein 1 (UCP1) and skeletal muscle UCP2 and UCP3 in MAC16-induced cachexia. Cancer Res. 2000;60:2405–2410
  24. Costelli P, Baccino FM. M Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care. 2003;6:407–412
  25. Langhans W. Peripheral mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care. 2002;5:419–426
  26. Williams AB, Decourten-Myers GM, Fischer JE, et al. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB J. 1999;13:1435–1443
  27. Costelli P, Tullio RD, Baccino FM, et al. Activation of Ca (2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer. 2001;84:946–950
  28. Costelli P, Bossola M, Muscaritoli M, et al. Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca (2+)-dependent proteolytic systems in the muscle of tumour-bearing rats. Cytokine. 2002;19:1–5
  29. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature. 1996;379:739–742
  30. Tisdale MJ. The ‘cancer cachectic factors’. Support Care Cancer. 2003;11(2):73–78
  31. Cariuk P, Lorite MJ, Todorov PT, et al. Indiction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer. 1997;76:606–613
  32. Lorite MJ, Thompson MG, Drake JL, et al. Mechanisms of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer. 1998;78:850–856
  33. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13–21
  34. Tiao G, Hobler S, Wang JJ, et al. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest. 1997;99:163–168
  35. Fang CH, Li BG, Fischer DR, et al. Burn injury upregulates the activity and gene expression of the 20S proteasome in rat skeletal muscle. Clin Sci. 2000;99:181–187
  36. Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest. 1996;97:1447–1453
  37. Costelli P, Carbó N, Tessitore L, et al. Tumour necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92:2783–2789
  38. Baracos VE, DeVivo C, Hoyle DH, et al. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995;268(5 Pt 1):E996–E1006
  39. Costelli P, Garcia-Martinez C, Llovera M, et al. Muscle protein wasting in tumour-bearing rats is effectively antagonized by a beta2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. J Clin Invest. 1995;95:2367–2372
  40. Llovera M, Garcia-Martinez C, Agell N, et al. Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett. 1994;338:311–318
  41. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1518–R1523
  42. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates whit disease severity in gastric cancer patients. Ann Surg. 2003;237(3):384–389
  43. Solomon V, Lecker SH, Goldberg AL. The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal. J Biol Chem. 1998;273:25216–25222
  44. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–1708
  45. Lecker SH, Jagoe T, Gilbert , et al. Multiple types of skeletal muscle atrophy involve a common program of changes in genes expression. FASEB J. 2004;18:39–51
  46. Guttridge DC, Mayo MW, Madrid LW, et al. NF-kappaB-induced loss of MyoD messenger RNA possible role in muscle decay and cachexia. Science. 2000;289:2363–2366
  47. Sabourin LA, Rudnicki MA. The molecular regulation of myogenesis. Clin Genet. 2000;57(1):16–25
  48. Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumour-bearing rats is associated with MyoD down-regulation. Int J Oncol. 2005;26:1663–1668
  49. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98:9306–9311
  50. Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997;67:12457–12461
  51. Carlson CJ, Booth FW, Gordon SE. Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol. 1999;46:R601–R606
  52. Lalani R, Bhasin S, Byhower F, et al. Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol. 2000;167:417–428
  53. Wehling M, Cai B, Tidball JG. Modulation of myostatin expression during modified muscle use. FASEB J. 2000;14:103–110
  54. Gonzalez-Cadavid NF, Taylor WE, et al. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA. 1998;95:14938–14943
  55. Reardon KA, Davis J, Kapsa RM, et al. Myostatin, insulin-like growth factor-1, and leukemia inhibitory factor mRNAs are upregulated in chronic human disuse muscle atrophy. Muscle Nerve. 2001;24:893–899
  56. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486–1488
  57. Muscaritoli M, Bossola M, Bellantone R, et al. Therapy of muscle wasting in cancer: what is the future?. Curr Opin Clin Nutr Metab Care. 2004;7:459–466
  58. Lopez AP, Roque Figuls M, Cuchi GU, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Sympt Manag. 2004;27:360–369
  59. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key?. Cancer Res. 1999;59:4493–4501
  60. Loprinzi CL, Kugler JW, Sloan JA. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17:3299–3306
  61. Argiles JM, Meijsing SH, Palares-Trujillo J, et al. Cancer cachexia: a therapeutic approach. Med Res Rev. 2001;21:83–101
  62. Klein TW, Lane B, Newton CA, et al. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000;225:1–8
  63. Fide E, Bregman T, Kirkham TC. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood). 2005;230(4):225–234
  64. Jatoi A, Windschiltl HE, Loprinzi CL, et al. Dronabinol versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment study. J Cin Oncol. 2002;20:567–573
  65. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657–2662
  66. Edelman MJ, Gandara DR, Meyers FJ, et al. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999;86:684–688
  67. Kaegi E. Unconventional therapies for cancer: Hydrazine sulfate. CMAJ. 1998;158(10):1327–1330
  68. Vickers A. Alternative cancer cures: “Unproven” or “Disproven. CA Cancer J Clin. 2004;54:110–118
  69. Hainer MI, Tsai N, Komura ST, et al. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med. 2000;133(11):877–880
  70. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622–634
  71. Bozzetti F, Gavazzi C, Mariani L, et al. Artificial nutrition in cancer patients: which route, what composition?. World J Surg. 1999;23(6):577–583
  72. Bruera E, Sweeney C. Cachexia and asthenia in cancer patients. Lancet Oncol. 2000;1(Nov):138–147
  73. Mercadante S. Parenteral versus enteral nutrition in cancer patients: indications and practice. Support Care Cancer. 1998;6(2):85–93
  74. Khursheed NJ. Total parenteral nutrition: potion or poison?. Am J Clin Nutr. 2001;74:160–163
  75. Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Dietary counseling improves patients outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005;23(7):1431–1438
  76. Combaret L, Ralliere C, Taillandier D, et al. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of the 20S and 26S proteasomes in muscles from tumour bearing rats. Mol Biol Rep. 1999;26:95–101
  77. Peuckmann V, et al. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273–292
  78. Lundholm K, Daneryd P, Korner U, et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol. 2004;24:505–512
  79. Davis TW, Zweifel BS, O’Neal JM, et al. Inhibition of cyclooxygenase- by celecoxib reverses tumour-2 induced wasting. J Pharmacol Exp Ther. 2004;308:929–934
  80. Muscaritoli M, Costelli P, Bossola M, et al. Effects of simvastatin administration in an experimental model of cancer cachexia. Nutrition. 2003;19:936–939
  81. Strassmann G, Fong M, Freter CE, et al. Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest. 1993;92:2152–2159
  82. Mori K, Fujimoto-Ouchi K, Ishikawa T, et al. Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer. 1996;67:849–855
  83. Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology. 1995;136:3669–3672
  84. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in treatment of neoplastic cachexia. Eur J Cancer. 1996;32:1340–1343
  85. Goldberg RM, Loprinzi CL, Maillard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo controlled trial. J Clin Oncol. 1995;13:2856–2859
  86. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739–758
  87. Hobler SC, Tiao G, Fischer JE, et al. Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am J Physiol. 1998;274:R30–R37
  88. Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604–3609
  89. Wigmore SJ, Barber MD, Ross JA. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177–184
  90. Fearon KC, von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense n−3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479–1486
  91. Moses AWG, Slater C, Preston T, et al. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n−3 fatty acids. Br J Cancer. 2004;90:996–1002
  92. Jatoi A, Kendrith R, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both patients with cancer-associated wastig :a north central cancer treatment group and national cancer institute of Canada colaborative efforts. J Clin Oncol. 2004;22(12):24692476
  93. Sachek JM, Ohtsuka A, McLary SC, et al. IGF-1 stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004;287(4):E591–E601
  94. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition. 2001;17(1 Suppl):S1–S20
  95. Sheffield Moore M. Androgens and the control of skeletal muscle protein synthesis. Ann Med. 2000;32:181–186
  96. Demling RH, DeSanti L. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns. 2003;29:793–797
  97. Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enteral Nutr. 2002;26:357–365
  98. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest. 2003;124:1733–1742
  99. Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer. 1986;58:183–186
  100. Tchekmedyian S, Fesen M, Price LM, et al. Ongoing placebo-controlled study of oxandrolone in cancer-related weight loss. Int J Radiat Oncol Biol Phys. 2003;57(2 Suppl):S283–S284
  101. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993;158:346–348
  102. Abu-Shajra S, Alhalabi MS, Nachtman FC, et al. Anabolic steroids induce injury and apoptosis of differentiated skeletal muscle. J Neurosci Res. 1997;47:186–197
  103. Whittemore LA, Song K, Li X, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun. 2003;300:965–971
  104. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996;76:1005–1026
  105. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev. 1995;16:3–34
  106. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the Insulin-like growth factor system in myogenesis. Endocr Rev. 1996;17:481–517
  107. Musaro A, Mc Cullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genet. 2001;27:195–200
  108. Alila H, Coleman M, Nitta H, et al. Expression of biologically active human insuline-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gen Ther. 1997;8:1785–1795
  109. Barton-Davis ER, Shoturma DI, Musarò A, et al. Viral mediated expression of insulin-like growth factor-1 blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95:15603–15607
  110. Jeschke MG, Barrow RE, Hawkins HK, et al. IGF-I gene transfer in thermally injured rats. Gene Ther. 1999;6:1015–1020
  111. Shiotani A, Fukumara M, Maeda M, et al. Skeletal muscle regeneration after insulin-like growt factor-1 gene transfer by recombinant Sendai virus vector. Gene Ther. 2001;8:1043–1050
  112. Takahashi T, Ishida K, Itoh K, et al. IGF-I gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Ther. 2003;10:612–620
  113. Alzghoul MB, Gerrard D, Watkins BA, et al. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB J. 2004;18:221–223
  114. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol. 2003;5:87–90
  115. Bischoff R. The satellite cell and muscle regeneration. In:  Engel AG,  Franszini-Armstrong C editor. Myogenesis. vol. 2:New York: McGraw-Hill; 1994;p. 97–118
  116. Rosenblatt JD, Parry DJ. Gamma irradiation prevents compensatory hypertrophy of overloaded mouse extensor digitorum longus muscle. J Appl Physiol. 1992;73:2538–2543
  117. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1 induced skeletal myotube hypertrophy by PI (3)K/Akt/mTOR and PI (3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3:1009–1013
  118. Bodine S, Stitt TN, Gonzales M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivio. Nat Cell Biol. 2001;3:1014–1019
  119. Lazarus DD, Kambayashi T, Lowry SF, et al. (The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-26-mediated cancer cachexia. Cancer Lett. 1996;103:71–77
  120. Mauras N, Horber FF, Haymond MW. Low-dose recombinant human IGF-1 fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metabol. 1992;75:1192–1197
  121. Yarwood GD, Ross RJ, Medbak S, et al. Administration of human recombinant IGF-1 in critically ill patients. Crit Care Med. 1997;25:1352–1361
  122. Young SC, Underwood LE, Celniker A, et al. Effects of recombinant IGF-1 and growth hormone on serum IGF-binding proteins in calorically restricted adults. J Clin Endocrinol Metab. 1992;75:603–608
  123. Ballard FJ, Walton PE, Bastian S, et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul. 1993;3:40–44
  124. Svanberg E, Ohlsson C, Kimball SR, et al. RhIGF-1/IGFBP-3 complex, but not free rhIGF-1, supports muscle protein biosynthesis in rats during semistarvation. Eur J Clin Invest. 2000;30:438–446
  125. Wang W, Iresjo BM, Karlsson L, et al. Provision of rhIGF-1/IGFBP3 complex attenuated development of cancer cachexia in an experimental tumour model. Clin Nutr. 2000;19:127–132
  126. Zdanowich MM, Teichberg S. Effects of insulin-like growth factor-1/binding protein-3 complex on muscle atrophy in rats. Exp Biol Med. 2003;228:891–897
  127. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. J Clin Pathol Mol Pathol. 2001;54:145–148
  128. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3:298–302
  129. Liu F, Liang KW, Huang L. Systemic administration naked DNA: gene transfer to skeletal muscle. Mol Inter. 2001;1(3):168–172
  130. Tone CM, Cardoza DM, Carpenter RH, et al. Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs. Cancer Gene Ther. 2004;11:389–396
  131. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10(8):828–834

PII: S0959-8049(05)00845-2

doi: 10.1016/j.ejca.2005.07.026

European Journal of Cancer
Volume 42, Issue 1 , Pages 31-41 , January 2006

Article Tools

* Image Usage & Resolution